TY - JOUR T1 - Association of COVID-19 with risks of hospitalization and mortality from other disorders post-infection: A study of the UK Biobank JF - medRxiv DO - 10.1101/2022.03.23.22272811 SP - 2022.03.23.22272811 AU - Yong Xiang AU - Ruoyu Zhang AU - Jinghong Qiu AU - Hon-Cheong So Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/23/2022.03.23.22272811.abstract N2 - Background More than 0.4 billion cases of COVID-19 have been reported worldwide. The sequalae of COVID-19 remains unclear, especially whether it may be associated with increased hospitalization and mortality from other diseases.Methods We leveraged a large prospective cohort of the UK biobank (UKBB) (N=412,096; current age 50-87) to identify associations of COVID-19 with hospitalization and mortality due to different diseases post-infection. We conducted a comprehensive survey on disorders from all systems (up to 135 disease categories). Multivariable Cox and Poisson regression was conducted controlling for main confounders. For sensitivity analysis, we also conducted separate analysis for new-onset and recurrent cases, and other sensitivity analysis such as the prior event rate adjustment (PERR) approach to minimize effects of unmeasured confounders.Results Compared to individuals with no known history of COVID-19, those with severe COVID-19 (requiring hospitalization) exhibited higher hazards of hospitalization and/or mortality due to multiple disorders (median follow-up=608 days), including disorders of respiratory, cardiovascular, neurological, gastrointestinal, genitourinary and musculoskeletal systems. Increased hazards of hospitalizations and/or mortality were also observed for injuries due to fractures, various infections and other non-specific symptoms. These results remained largely consistent after sensitivity analyses. Severe COVID-19 was also associated with increased all-cause mortality (HR=14.700, 95% CI: 13.835-15.619).Mild (non-hospitalized) COVID-19 was associated with modestly increased risk of all-cause mortality (HR=1.237, 95% CI 1.037-1.476) and mortality from neurocognitive disorders (HR=9.100, 95% CI: 5.590-14.816), as well as hospital admission from a few disorders such as aspiration pneumonitis, musculoskeletal pain and other general signs/symptoms.Conclusions In conclusion, this study revealed increased risk of hospitalization and mortality from a wide variety of pulmonary and extra-pulmonary diseases after COVID-19, especially for severe infections. Mild disease was also associated with increased all-cause mortality. Further studies are required to replicate our findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported partially a National Natural Science Foundation China (NSFC) grant (81971706) and the Lo Kwee Seong Biomedical Research Fund from The Chinese University of Hong Kong and the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Biobank study has received ethical approval from the NHS National Research Ethics Service North West (16/NW/0274). The current study was conducted under the project number 28732. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UK Biobank data is available to all registered researchers upon application. All other data produced in the present work are contained in the manuscript. ER -